Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT01037179 Completed - Clinical trials for Allergic Conjunctivitis

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

NCT ID: NCT01028027 Completed - Blepharitis Clinical Trials

Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

Start date: October 2009
Phase: Phase 3
Study type: Interventional

This study is to evaluate the safety and efficacy of loteprednol etabonate [LE] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).

NCT ID: NCT01013259 Completed - Rhinoconjunctivitis Clinical Trials

Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis

Ecorhino
Start date: February 2009
Phase: Phase 2
Study type: Interventional

Due to the worldwide increasing prevalence of the allergic rhinoconjunctivitis, new therapeutical strategies are needed. The symptomatic treatment with topical and systemic antihistamines and corticosteroids are often insufficient. E.coli Nissle 1917 has immunomodulatory capacities and reveals less side effects. E.coli Nissle 1917 has no sedative properties and exhibits no hepatotoxic qualities. Thus, E.coli Nissle 1917 represents a new relevant therapeutical agent.

NCT ID: NCT01012752 Not yet recruiting - Allergic Rhinitis Clinical Trials

A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts

Start date: October 2016
Phase: Phase 3
Study type: Interventional

This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.

NCT ID: NCT01001091 Completed - Clinical trials for Allergic Conjunctivitis

AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

NCT ID: NCT00987272 Completed - Clinical trials for Allergic Conjunctivitis

Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Start date: October 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.

NCT ID: NCT00985296 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

ABC CAC
Start date: September 2009
Phase: N/A
Study type: Observational

To evaluate the effect of Conjunctival Allergen Challenge (CAC) with Dust Mites on nasal and ocular allergic symptoms following allergen exposure in the Allergen BioCube (ABC).

NCT ID: NCT00985075 Completed - Clinical trials for Allergic Rhinoconjunctivitis

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

Start date: December 2008
Phase: N/A
Study type: Observational

The objective of this study is to evaluate ocular and nasal signs and symptoms in patients with seasonal allergic rhinoconjunctivitis following allergen exposure in the Allergen BioCube.

NCT ID: NCT00982163 Completed - Clinical trials for Allergic Conjunctivitis

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

Start date: August 2008
Phase: N/A
Study type: Observational

The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season. It was hypothesized that a pattern of ongoing ocular allergic inflammation existed in certain subjects.

NCT ID: NCT00978029 Completed - Allergy Clinical Trials

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.